Megestrol acetate

Name: Megestrol acetate
Brand: MedChemExpress
SKU: HY-13676
Rating: 5.0 (2 reviews)

Art. -Nr.: HY-13676 Reinheit: 99.69%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Megestrol acetate Chemische Struktur

CAS. Nr. : 595-33-5

Größe	Verfügbarkeit	Menge
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	Auf Lager	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	Auf Lager	Estimated Time of Arrival: December 31
Solid
500 mg	Auf Lager	Estimated Time of Arrival: December 31
1 g	Auf Lager	Estimated Time of Arrival: December 31
5 g	Auf Lager	Estimated Time of Arrival: December 31
10 g	Angebot einholen
50 g	Angebot einholen

or Massenanfrage

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Other Forms of Megestrol acetate:

Megestrol In-stock
Megestrol acetate (Standard) In-stock
Megestrol acetate-d₃ Angebot einholen
Megestrol acetate-d₃-1 Angebot einholen

2 Publications Citing Use of MCE Megestrol acetate

Spezialitätsempfehlungen

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Alle HIV Isoform-spezifische Produkte anzeigen:

Alle Isoformen anzeigen

HIV HIV-1 HIV-2

Biologische Aktivität
Reinheit & Dokumentation
Verweise
Kundenbewertung

Beschreibung

In Vitro

Megestrol acetate alone results in an ICKY of 48.7 p,M in the MCF7/ADR cell line^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Megestrol acetate (100 or 300 mg/kg, Subcutaneously daily over a 7-day period) is able to reduce the weight loss produced by both TNF and by the MAC16 tumour^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Pure strain female NMRI mice (age 6 to 8 weeks)^[1].
Dosage:	100 or 300 mg/kg (50 mg megestrol acetate was suspended in 3 ml of pure corn oil).
Administration:	Subcutaneously daily over a 7-day period.
Result:	Produced a highly significant reversal of the TNF-induced decrease in body weight, accompanied by a significant increase in both food and water intake. Caused an increase in body weight over a 24-hour period to female NMRI mice. No effect on blood glucose levels in saline controls, concurrent administration of megestrol acetate with TNF caused a significant increase in blood glucose compared with administration of TNF alone. Caused a dose-related reduction in the loss of host body weight in animals bearing the MAC16 tumour.

Molekulargewicht

384.51

Formel

C₂₄H₃₂O₄

CAS. Nr.

595-33-5

Appearance

Solid

Color

White to off-white

SMILES

CC([C@@]1(OC(C)=O)CC[C@@]2([H])[C@]3([H])C=C(C)C4=CC(CC[C@]4(C)[C@@]3([H])CC[C@]12C)=O)=O

Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 20 mg/mL (52.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6007 mL	13.0036 mL	26.0071 mL
5 mM	0.5201 mL	2.6007 mL	5.2014 mL
10 mM	0.2601 mL	1.3004 mL	2.6007 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner
Verdünnungsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2 mg/mL (5.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2 mg/mL (5.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2 mg/mL (5.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Reinheit & Dokumentation

Purity: 99.69%

Select Batch:

Data Sheet (279 KB) SDS (418 KB)

COA (253 KB) RP-HPLC (209 KB)

Handling Instructions (2659 KB)

Verweise

[1]. S A Beck, et al. Effect of megestrol acetate on weight loss induced by tumour necrosis factor alpha and a cachexia-inducing tumour (MAC16) in NMRI mice. Br J Cancer. 1990 Sep;62(3):420-4. [Content Brief]

[2]. L Panasci, et al. Sensitization to doxorubicin resistance in breast cancer cell lines by tamoxifen and megestrol acetate. Biochem Pharmacol. 1996 Oct 11;52(7):1097-102. [Content Brief]

[3]. J Geller, et al. Acute therapy with megestrol acetate decreases nuclear and cytosol androgen receptors in human BPH tissue. Prostate. 1982;3(1):11-5. [Content Brief]

[4]. J H von Roenn, et al. Megestrol acetate for treatment of cachexia associated with human immunodeficiency virus (HIV) infection. Ann Intern Med. 1988 Nov 15;109(10):840-1. [Content Brief]

[5]. Vincenzo Musolino, et al. Megestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulation. J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):555-566. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6007 mL	13.0036 mL	26.0071 mL	65.0178 mL
	5 mM	0.5201 mL	2.6007 mL	5.2014 mL	13.0036 mL
	10 mM	0.2601 mL	1.3004 mL	2.6007 mL	6.5018 mL
	15 mM	0.1734 mL	0.8669 mL	1.7338 mL	4.3345 mL
	20 mM	0.1300 mL	0.6502 mL	1.3004 mL	3.2509 mL
	25 mM	0.1040 mL	0.5201 mL	1.0403 mL	2.6007 mL
	30 mM	0.0867 mL	0.4335 mL	0.8669 mL	2.1673 mL
	40 mM	0.0650 mL	0.3251 mL	0.6502 mL	1.6254 mL
	50 mM	0.0520 mL	0.2601 mL	0.5201 mL	1.3004 mL